Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anabela Cardoso

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
The Lancet. Respiratory Medicine|September 4, 2021
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trialVincent C Marconi, Athimalaipet V Ramanan, Stephanie de Bono, et al.
EMBO Molecular Medicine|May 31, 2020
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patientsJustin Stebbing, Venkatesh Krishnan, Stephanie de Bono, et al.
Acta Reumatologica Portuguesa|May 28, 2010
Portuguese guidelines for the use of biological agents in rheumatoid arthritis - March 2010 updateJoão Eurico Fonseca, Helena Canhão, Paulo Reis, et al.
Acta Reumatologica Portuguesa|April 5, 2012
Portuguese guidelines for the use of biological agents in rheumatoid arthritis - October 2011 updateJoão Eurico Fonseca, Miguel Bernardes, Helena Canhão, et al.
The New England Journal of Medicine|December 11, 2020
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19Andre C Kalil, Thomas F Patterson, Aneesh K Mehta, et al.
The Lancet. Respiratory Medicine|May 26, 2022
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trialCameron R Wolfe, Kay M Tomashek, Thomas F Patterson, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
The Lancet. Respiratory Medicine|September 4, 2021
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trialVincent C Marconi, Athimalaipet V Ramanan, Stephanie de Bono, et al.
EMBO Molecular Medicine|May 31, 2020
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patientsJustin Stebbing, Venkatesh Krishnan, Stephanie de Bono, et al.
Acta Reumatologica Portuguesa|May 28, 2010
Portuguese guidelines for the use of biological agents in rheumatoid arthritis - March 2010 updateJoão Eurico Fonseca, Helena Canhão, Paulo Reis, et al.
Acta Reumatologica Portuguesa|April 5, 2012
Portuguese guidelines for the use of biological agents in rheumatoid arthritis - October 2011 updateJoão Eurico Fonseca, Miguel Bernardes, Helena Canhão, et al.
The New England Journal of Medicine|December 11, 2020
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19Andre C Kalil, Thomas F Patterson, Aneesh K Mehta, et al.
The Lancet. Respiratory Medicine|May 26, 2022
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trialCameron R Wolfe, Kay M Tomashek, Thomas F Patterson, et al.
Pageof 3